# Junta clínica — PT-pseudo_c12bcf838ec8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c12bcf838ec8",
  "pid": "PT-pseudo_c12bcf838ec8",
  "task": 1,
  "psa": 3.4,
  "age": 63,
  "months": 2,
  "pirads": "3",
  "psad": 0.05,
  "psav": -0.28,
  "psap": 3.5,
  "vol": 58.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.71182245,
  "medhx": "Obesity (BMI >30), Osteoarthritis",
  "meds": "paracetamol PRN",
  "notes": "PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.",
  "pmhx": [
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "183 cm",
    "bmi": "22.4",
    "bp": "111/68 mmHg",
    "hr": "68 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2011)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Feb 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available."
    },
    {
      "s": "History",
      "t": "First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Gastroenterology — surveillance colonoscopy"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c12bcf838ec8
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.05 ng/mL²
  - PSA velocity: -0.28 ng/mL/yr
  - Prior PSA: 3.5 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.71182245 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Obesity (BMI >30), Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.

Vitals: weight 75 kg, height 183 cm, BMI 22.4, BP 111/68 mmHg, HR 68 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2011).

Chief complaint: A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available.

History: First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent.

Patient info: retired bank clerk; Divorced; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Tennis 2x/week; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Gastroenterology — surveillance colonoscopy.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.31
  uncertainty  +/- 0.12 (95% CI 0.08-0.54); among patients it cannot tell apart the outcome was 0.89 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. It notes that applying a PSA-D cut-off of $0.15 \text{ ng/mL/cc}$ would have avoided $817$ biopsy procedures while missing $6.5\%$ of ISUP $\ge 2$ cancer. Furthermore, a PI-RADS threshold of $\ge 4$ would have avoided $59\%$ of all biopsy procedures while missing $28\%$ of detected ISUP $\ge 2$ cancers.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of 'NO BIOPSY' is not sufficiently informed by the guideline's risk stratification. The guideline provides specific thresholds for PI-RADS scores and PSA density that can be used to guide the decision, which the classifier's limited variables failed to incorporate. The classifier cannot account for the guideline's recommendation regarding the trade-off between avoiding biopsies and missing cancer, which is a variable the guideline makes decisive.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on stability.
PSA trend - The PSA velocity is $-0.28 \text{ ng/mL/yr}$, which is a finding that the guideline makes decisive regarding risk assessment.
Previous notes - The previous notes state the prior biopsy was negative, which is a finding that the guideline makes decisive regarding the need for repeat biopsy.
Laboratory results - The PSA density is $0.05 \text{ ng/mL/cc}$, which is a finding that the guideline makes decisive regarding risk assessment.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 3 score, combined with the negative prior biopsy and the PSA velocity, warrants a repeat biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current findings against an earlier study.
  psa_trend (get_psa_trend) -> Assess the significance of the PSA velocity in the context of the guideline recommendations.
  previous_notes (get_previous_notes) -> Confirm the management context regarding the prior negative biopsy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  Q2. Does the PSA trend provide sufficient information to guide the decision regarding the need for re-biopsy?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates that the current findings are not explicitly compared against an earlier study.
psa_trend
The PSA velocity is $-0.28 \text{ ng/mL/yr}$.
previous_notes
The previous notes confirm the management context regarding the prior negative biopsy, stating a referral was initiated for further evaluation and imaging consideration.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them in the plan, and the key variables for the decision were covered by the other requested documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The previous notes confirm the management context regarding the prior negative biopsy.
The PSA trend provides sufficient information to guide the decision regarding the need for re-biopsy.
AGAINST sampling this patient now
The mpMRI prose does not compare against an earlier study.

WHERE THIS LEANS
The information gathered confirms that the mpMRI does not provide the comparison needed by the guideline, leaving the decision dependent on the PSA trend and prior notes.
LEAN: unclear

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the mpMRI prose does not compare the current findings against an earlier study, and Q2 by stating the PSA velocity provides sufficient information. However, the laboratory results remain closed.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-EAU's need for the PSA trend and previous notes, which the classifier missed, suggesting the classifier's 'NO BIOPSY' bid was incomplete.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose indicate whether the lesion is compared against an earlier study? Answered by the registrar, who stated it does not.
Q2. Does the PSA trend provide sufficient information to guide the decision regarding the need for re-biopsy? Answered by the registrar, who stated it does.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (3), the prior biopsy status (negative), and the PSA velocity ($-0.28 \text{ ng/mL/yr}$). The PI-RADS score matters because it sets the initial threshold, the prior negative biopsy matters because it is a key context for repeat sampling, and the PSA velocity matters because the guideline makes this decisive for risk assessment. The room has leaned on the PI-RADS 3 score, but the guideline does not support proceeding based on it alone without the other factors.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the PSA trend and prior notes provide the necessary context that the guideline requires to move beyond the PI-RADS 3 score alone.

VERDICT: ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

I defer the biopsy recommendation because the Expert-Cohort criterion matched the reading urologist in 16 of 18 cases with a prior negative biopsy. The retrieved documents confirmed that the mpMRI did not compare against an earlier study, and the PSA velocity was $-0.28 	ext{ ng/mL/yr}$. The Expert-Cohort's finding that repeat biopsy is not warranted for an unchanged PI-RADS 3 picture is highly relevant here.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=important
Documents this conference opened: radiology_report, psa_trend, previous_notes
